In today’s recent session, 0.83 million shares of the Protalix BioTherapeutics Inc (AMEX:PLX) have been traded, and its beta is 0.64. Most recently the company’s share price was $1.65, and it changed around $0.25 or 17.86% from the last close, which brings the market valuation of the company to $120.64M. PLX at last check was trading at a discount to its 52-week high of $1.90, offering almost -15.15% off that amount. The share price’s 52-week low was $0.82, which indicates that the recent value has risen by an impressive 50.3% since then. We note from Protalix BioTherapeutics Inc’s average daily trading volume that its 10-day average is 0.46 million shares, with the 3-month average coming to 191.02K.
Protalix BioTherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended PLX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Protalix BioTherapeutics Inc is expected to report earnings per share of 0.08 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Protalix BioTherapeutics Inc (AMEX:PLX) trade information
Instantly PLX has been showing a green trend so far today with a performance of 17.86% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -7.30% year-to-date, but still up 37.50% over the last five days. On the other hand, Protalix BioTherapeutics Inc (AMEX:PLX) is 51.38% up in the 30-day period. We can see from the shorts that 3.1 million shares have been sold at a short interest cover period of 22.71 day(s).
Protalix BioTherapeutics Inc (PLX) estimates and forecasts
Protalix BioTherapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 37.50 percent over the past six months and at a -33.33% annual growth rate that is well below the industry average of 17.50%. The year-over-year growth rate is expected to be 90.01%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 18.21M in revenue for the current quarter. 1 analysts expect Protalix BioTherapeutics Inc to make 53.39M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.49M and 65.49M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 73.62%. Forecasts for the next quarter put sales growth at -18.49%.
Protalix BioTherapeutics Inc earnings are expected to increase by -77.78% in 2024, but the outlook is positive 25.00% per year for the next five years.
PLX Dividends
Protalix BioTherapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-14.
Protalix BioTherapeutics Inc (AMEX:PLX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 14.53% of Protalix BioTherapeutics Inc shares, and 5.20% of them are in the hands of institutional investors. The stock currently has a share float of 6.08%. Protalix BioTherapeutics Inc stock is held by 54.0 institutions, with MILLENNIUM MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 1.1106% of the shares, which is about 0.81 million shares worth $0.95 million.
RENAISSANCE TECHNOLOGIES LLC, with 1.1016% or 0.8 million shares worth $0.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
